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Abstract 
The course of patients after and admission for acute heart failure (AHF), especially length of initial 
hospital stay (LOS), rate of early readmission and death are of major importance to patients and health 
providers. We explored these outcomes in 1,990 patients enrolled in the PROTECT study. 
Methods: The PROTECT study examined the effect of the adenosine blocker rolofylline in patients within 
24 hours of admission for AHF with mild to moderate renal impairment. We examined predictors and 
associations of LOS, 30-day readmission and 90-day mortality in the study.  
Results: LOS was only partially predicted by severity of HF and other background morbidities at baseline  
(diabetes mellitus, renal impairment, ischemic heart disease) as well as severity of metabolic 
dysfunction (cholesterol and albumin) at baseline and their changes during the first days of admission. 
Occurrence of in-hospital worsening heart failure (WHF) was associated with significant increase in LOS. 
Thirty-day readmissions and especially HF readmissions were associated with more severe HF and 
previous HF admission but not with LOS. Death within 90 days after discharge was associated with older 
age, more severe HF, worse renal function and lower sodium and bicarbonate at admission. LOS was a 
strong predictor of 90-day post-discharge mortality. 
Conclusions: In patients admitted for AHF, LOS is not well-predicted by traditional markers of disease 
severity, but strongly associated with the occurrence of in-hospital WHF. After discharge, early 
readmissions are mostly predicted by previous HF admissions and severity of HF, while 90-day mortality 
is more strongly associated with HF severity, renal impairment and advanced age. Longer LOS is a strong 
predictor of early mortality even after discharge but not of readmissions.   These findings may help focus 
efforts to reduce LOS and post-discharge outcomes on patients’ subgroups at increased risk.  
 
Hospitalization for acute heart failure (AHF) is a major cause of morbidity and mortality and a significant 
burden on healthcare systems worldwide [1] [2] . The patients’ journey after being admitted 
encompasses several important possible outcomes including a long length of stay (LOS) during the initial 
hospitalization, followed by a high risk for repeat readmissions (most of which are for heart failure) and 
an increased risk of death [2]. Although all of these outcomes have been examined as measures of 
treatment success and, in some jurisdictions suggested as surrogate measures of hospital performance , 
they tend to vary substantially, especially among countries and geographic regions [3-6],  and, given a 
lack of understanding of their predictors, tools to influence these outcomes globally are missing. This is 
especially true for LOS, where uncertainty surrounds what constitutes the optimal length of stay, given 
that some studies suggest that short LOS may be associated with a higher rate of  readmission or even 
death [7, 8]. To better understand the implications of predictors of these outcome measures and 
differences in LOS across different countries, we studied patient outcomes in hospital and up to 90 days 
after admission, adjusted for regional LOS disparities, among the 1,990 patients with AHF enrolled 
within 24h of admission into the Placebo-controlled Randomized study of the selective A1 adenosine 
receptor antagonist KW-3902 for patients hospitalized with acute HF and volume Overload to assess 
Treatment Effect on Congestion and renal function (PROTECT)[9]. 
Methods: 
Inclusion Criteria and Study Design:  PROTECT was initially designed as two identical, concurrent 
randomized, placebo-controlled trials (PROTECT-1 and PROTECT-2; ClinicalTrials.gov numbers, 
NCT00328692 and NCT00354458, respectively), which were then combined for analysis.  The design and 
main results of PROTECT have been published [9], [10].  Patients with pre-existing heart failure, mild or 
moderate renal impairment (estimated creatinine clearance, 20–80 mL/min), increased plasma 
concentrations of brain natriuretic peptides, and dyspnea at rest or minimal exertion associated with 
symptoms and signs of volume overload requiring intravenous diuretic therapy, were enrolled within 24 
hours of admission.  The protocol was approved by the ethics committee at each participating center, 
and patients provided written informed consent. 
During the initial hospitalization, patients were assessed daily through the earlier of day 7 or discharge, 
followed up on day 14, and then contacted by telephone to identify death and readmission up to day 60 
and to assess vital status alone at day 180.  Investigators reported the occurrence of worsening heart 
failure (WHF) during the initial hospitalization based on worsening signs or symptoms of heart failure 
leading to intensification of HF-directed therapy.  Samples for central laboratory assessment of 
chemistry and hematology were drawn daily through day 4 and then at day 7.  Results of primary and 
secondary end points of PROTECT have been reported in detail. [9] For the purposes of this analysis, the 
following outcomes were considered: length of initial hospital stay, 30-day post-discharge all-cause 
readmission, 30-day post-discharge heart failure readmission, and 90-day post-discharge all-cause 
mortality. 
Statistical Methods: Patients in the intention-to-treat analysis set were excluded who were missing 
information about whether or not the patient had died during the initial hospital stay and therefore 
were missing a record for LOS. Length of stay is presented by patient status (survived or died during 
initial hospital stay) and by geographical region, showing means, standard deviations, medians, and first 
and third quartiles. For all subsequent analyses, patients who died during the initial hospital stay have 
been excluded.  Because readmissions were assessed only through 60 days after baseline, patients with 
a LOS longer than 30 days were further excluded from analyses of 30-day post-discharge readmissions. 
The following endpoints were considered for analysis: (i) LOS, (ii) 30-day post-discharge all-cause 
readmission, (iii) 30-day post-discharge HF readmission, and (iv) 90-day post-discharge all-cause 
mortality. Baseline characteristics are presented for patients who survived to discharge and further 
categorized as having a short, medium, or long LOS (supplementary tables). This categorization was 
determined based on the first and third tertiles within geographic region, which were 4 and 7 days in 
North America, 4 and 6 days in Israel, 8 and 13 days in Western Europe, 7 and 10 days in Eastern Europe, 
4 and 6 days in Argentina, and 15 and 18 days in Russia. Baseline characteristics are further presented by 
all-cause readmission up to 30 days after discharge, by HF readmission up to 30 days after discharge, 
and by all-cause mortality up to 90 days after discharge (supplementary tables). For continuous baseline 
variables means, standard deviations, medians, and first and third quartiles are presented and 
differences between groups are compared using ANOVA F-tests. For discrete baseline variables absolute 
and relative frequencies are presented and proportions are compared between groups using chi-square 
tests.   
Univariable and multivariable associations between baseline characteristics and each endpoint were 
assessed using linear regression (for LOS), logistic regression (for 30-day post-discharge readmission 
endpoints), and Cox proportional hazards models (for 90-day post-discharge mortality).  Multivariable 
models were developed using a common approach.  Non-linearity of the association between each 
continuous predictor and the outcome was assessed through testing the significance of non-linear 
components of a restricted cubic spline transformation.  Plots of the predicted outcome against the 
value of the predictor and values of Akaike’s Information Criterion (AIC) were used to select non-linear 
transformations where needed.  From the 44 baseline variables considered (presented in the 
supplementary tables), four parameters (pulse pressure, mean arterial pressure, eGFR, and 
BUN/creatinine ratio) were excluded from further consideration due to correlation and/or collinearity 
issues. Multiple imputation assuming multivariate normality was used for missing predictors; the 
proportion missing each covariate is given in the supplementary tables. In each of the 10 imputed data 
sets, backwards selection was performed at a 0.05 significance level for linear regression and a 0.10 
significance level for Cox and logistic regression models. Predictors selected in at least six of the ten 
imputed data sets were included in the final overall multivariable model. Estimated effect sizes, 
confidence intervals and p-values were obtained by averaging across the imputation datasets using 
Rubin’s algorithm.[11] Model performance was assessed through adjusted R-squared for linear 
regression models and through C-statistics for logistic regression and Cox proportional hazards models. 
C-statistics for Cox regression were computed using Harrell’s method. [12, 13] Observed adjusted R-
squared and C-statistics were averaged across the 10 imputed data sets and further examined by 
obtaining bias-corrected estimates and corresponding confidence intervals using bootstrapping. 
A multivariable-adjusted estimate of the association between LOS and the outcome of interest was 
obtained by adding the LOS as a predictor in the multivariable model.  The occurrence of WHF up to day 
7 after baseline was then added to evaluate whether any association between LOS and the outcome 
might be explained by WHF.  In addition, changes from baseline to day 2 for certain laboratory 
parameters (albumin, AST, cholesterol, and creatinine) as well as for weight were added both 
individually and all at once into the model to determine how these parameters affect the association 
between LOS and the outcome of interest. Differences between models with added parameters were 
examined by obtaining bootstrap estimates and confidence intervals for the differences in adjusted R-
squared or C-statistics. All models were either adjusted or stratified by geographic region.   
The rate of HF readmission as a function of days after discharge was evaluated using Poisson regression.  
Patients were considered at risk until the first readmission for HF, last follow-up, or death. Due to the 
low number of events per day post-discharge, the model was not adjusted by geographic region. 
SAS® version 9.3 (SAS Institute, Cary, NC, USA) software was used for all analyses. 
Results: 
Between May 2007 and January 2009, 2033 patients were enrolled in PROTECT.  . Of the 2021 patients 
in the intention-to-treat analysis set, 31 were excluded from analysis for whom deaths could not be 
classified as having occurred or not during the initial hospitalization. Therefore, no LOS value was 
available for these patients. For further analysis of LOS and all post-discharge endpoints, 88 patients 
who did not survive to discharge were excluded from the set of 1990 patients, leaving 1902 patients for 
analysis. For analysis of 30-day post-discharge readmissions, additional 53 patients whose LOS was > 30 
days were excluded, leaving 1849 patients for analysis. 
LOS: Length of stay (LOS) for patients who did and did not survive the initial hospitalization is presented 
by geographic region in table 1. Baseline characteristics of patients discharged alive by LOS categories 
(short, intermediate and long) are presented in Supplementary table 1. Univariable and multi variable 
associations of baseline characteristics with LOS are presented in table 2a. Variables associated with 
shorter length of stay included male sex, history of HF, and higher systolic blood pressure, WBC, albumin 
and cholesterol (up to 4.5 mg/dl). Variables associated with longer LOS included history of angina 
pectoris, history of diabetes mellitus, higher BMI, higher heart rate (above 90 beats per minute at 
admission), more orthopnea and higher JVP, and higher BUN and Uric acid. In general the model had 
poor to modest ability to predict LOS in patients with AHF, with a bias-corrected adjusted R-square of 
0.27. Adding to the model changes occurring during the first days of admission that representing 
congestion and end organ damage – such as AST, weight and creatinine changes, previously shown to be 
associated with post-discharge outcomes in protect  [14]  did not significantly improve the model. 
However, changes in markers of metabolic abnormalities such as Cholesterol and albumin and especially 
the occurrence of in-hospital WHF through day 7 increased the bias-corrected adjusted R-squared to 
0.32 (95% CI 0.27, 0.35) which constitutes a significant increase of 0.050 (95% CI 0.028, 0.072), (table 
2b). Mean LOS was 15.2 days in patients with in-hospital WHF versus 9.8 days in patients without in-
hospital WHF.  
Readmission within 30 days after discharge: Baseline characteristics for patients who were or were not 
readmitted in the first 30 days post discharge are presented in supplemental table 2a, and baseline 
characteristics for patients readmitted for HF during the first 30 days after discharge are presented in 
supplemental table 2b. The HF readmission rate tended to follow a quadratic pattern of early increase 
during the first few days after discharge followed by a decrease (p=0.0458, figure 1). Multivariate 
predictors of all cause readmission 30 days after discharge were diabetes mellitus, presence of 
orthopnea but lack of edema and increased BUN (Table 3a). The bias-corrected C-index for the model 
was 0.68 suggesting that the model had low predictive value. Longer LOS was borderline significant 
predictor for increased rate of all cause readmissions after discharge (p=0.0525) without improving the 
c-index of the model.  
Previous HF admission, orthopnea at admission, lower sodium, higher BUN and higher albumin were 
associated with an increased risk for HF readmission within 30 days after discharge (table 3b). The bias-
corrected C-index for this model was higher (0.74) than for all-cause readmission. Neither LOS nor 
occurrence of WHF were significantly associated with higher rates of 30-day post-discharge readmission 
and did not add predictive value to the model.  Cumulative risks of post-discharge HF readmission by 
history of HF admission prior to the initial admission are presented in figure 2.  
90-day post-discharge mortality: Baseline characteristics of patients who died within 90 days of 
discharge are presented in supplemental table 3. Older age, history of lung disease, lower systolic blood 
pressure at admission, higher WBC count, lower sodium and bicarbonate and higher BUN and uric acid 
were associated with increased risk of mortality 90 days post discharge. Longer LOS, up to 14 days was 
associated with higher 90-day post-discharge mortality and this association persisted even after 
adjustment for WHF (table 4) as well as changes in albumin, AST, cholesterol, creatinine, and weight to 
day 2 (table 5). The model has modest discrimination for the outcome (bias-corrected c-index = 0.73).  
Discussion 
The journey of patients admitted for acute heart failure (AHF) through the hospitalization and early 
post-discharge period has been of significant interest in recent years as AHF has become an increasingly 
common cause for hospital admission [1] and admission for AHF is a large driver of the health cost 
associated with HF. Therefore, determining the drivers of longer LOS and, for patients being discharged 
alive, the drivers for early readmission and death has gained substantial importance.  
Length of the initial hospital stay has been difficult to analyze because of its extreme variation among 
geographic regions [3-6]. Indeed, in the present analysis LOS varied between 5-6 days in Argentina, 
Israel and the US to 17 days in Russia. After accounting for geographic region, the multivariable model to 
predict longer LOS had low to modest discrimination, meaning that for the most part variables such as 
baseline severity of HF, concomitant disease and lab abnormalities at admission did not predict well the 
LOS. Addition of in-hospital measures of changes in disease severity such as worsening of end organ 
(kidney, liver) function as well as change in weight, which in AHF patients mostly represents 
decongestion did not significantly improve the model, suggesting that these changes, did not add 
beyond HF and renal impairment severity at baseline to the patients length of stay. On the other hand, 
metabolic changes (change in cholesterol and albumin) and most significantly the occurrence of in-
hospital WHF increased the ability to predict length of stay (table 2b). WHF was shown previously to be 
a strong predictor of LOS and short term outcomes in AHF [15-18] and the current analysis adds 
substantially to this body of knowledge, reinforcing the strong interaction between occurrence of WHF 
in hospital in patients with AHF and prolonged LOS. These findings are of interest as they do not support 
our tendency in clinical practice to look at decongestion and weigh as well as changes in organ function 
– most importantly kidney function as important determinants of patient “dischargability”. In reality, 
patients LOS is probably determined by severity of their disease and co-morbidities at baseline, 
however, during the hospital admission improvement in metabolic measures such as albumin and 
cholesterol and most importantly lack of occurrence of WHF are strong determinants of LOS, and hence 
it is possible that efforts to improve those measures and especially prevention of WHF should take 
precedence in our effort to shorten LOS. 
Early post-discharge admissions (for all causes and HF) during the first 30 days after discharge were less 
common in the first days after discharge increasing after approximately a week and then decreasing 
slowly over time (figure 1). HF readmissions were largely predicted by whether patients were previously 
admitted for HF, disease severity (congestion, low sodium) and renal dysfunction. Previous HF 
readmission (figure 2) was an especially strong predictor of additional HF readmissions within 30 days 
post-discharge. Regretfully in the PROTECT study we did not collect any socioeconomic data to assess 
whether these factors contribute substantially to the rate of early HF readmission. However, by the fact 
that readmissions were common mostly very close to discharge and mostly predicted by previous HF 
admission, it would be reasonable to assume that early HF readmissions may occur preferentially in a 
subgroup of patients who tend to be hospitalized more – some because their HF and renal impairment 
are more severe, but as suggested previously [14] some because of socioeconomic parameters and 
some because of area of living [6, 17] .  Interestingly, when examining the predictors of 90-day post-
discharge mortality, although some predictors for HF readmission and death are similar (such as 
congestion at admission and kidney function), others are not (such as age, blood pressure, WBC count). 
Most importantly increased length of stay remains a very significant predictor of 90-day post-discharge 
mortality, even after multiple adjustments for in-hospital deterioration of kidney or liver function or 
worsening of heart failure, but LOS is not a predictor of short term readmission, and especially HF 
readmission. Again, these associations suggest that to a certain degree a dichotomy exists in AHF 
between early readmission, and especially those for HF, and death. The current data as well as similar 
analysis of VERITAS [19] suggest that HF severity and more complicated hospital course are major 
drivers of post-discharge early mortality while early HF readmissions are driven by disease severity but 
possibly more so by a tendency of the patients to be repeatedly readmitted. If confirmed, this finding 
may have significant implications for targeting therapy. i.e., mortality should be targeted with the same 
tools aimed at improving heart failure and renal impairment, while readmission may need to be 
addressed by other interventions, aimed at patients who tend to be repeatedly admitted to hospitals. 
Limitations 
The current analysis is a retrospective analysis of the PROTECT study and hence limited to the patients 
who met the inclusion and exclusion criteria for the study and the variables collected in that study 
including only readmissions up to 60 days post discharge and no socioeconomic measures. The study 
was of relatively modest size and these results should be examined in larger prospective and possibly 
less selective patient populations.  
Conclusions 
For patients discharged alive from an admission for AHF, the main factors that are of importance to the 
patient and the health system as a whole are the length of initial hospital stay, and early readmission 
and death after discharge. The current analysis suggests that although heart failure and renal 
impairment contribute to prolonged LOS as well as increased rate of early readmission and death, other 
factors may contribute to the length of stay and tendency for early re-admission while early mortality is 
mostly driven by disease severity and comorbidities. These factors – in-hospital WHF for LOS and history 
of HF admissions for early post-discharge HF readmissions may prove important in targeting specific 
patients’ subgroups for interventions aimed at reducing LOS and post-discharge readmissions. 
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 Table 1: Length of stay by patient status and region. 
 
---- Subjects who survived to discharge ---- 
(N = 1902) 
Subjects who died during initial hospital stay 
(N = 88) 
------------------------ Total ------------------------ 
(N = 1990) 
Region 
Number of 
subjects Length of stay, days [1] 
Number of 
subjects Length of stay, days [1] 
Number of 
subjects Length of stay, days [1] 
North America 296 (15.6%) 6.9 (5.60), 5.0 (4.0 - 8.0) 7 (8.0%) 21.0 (11.08), 18.0 (12.0 - 31.0) 303 (15.2%) 7.3 (6.13), 5.0 (4.0 - 8.0) 
Israel 306 (16.1%) 6.0 (4.11), 5.0 (4.0 - 7.0) 6 (6.8%) 10.7 (3.61), 11.0 (9.0 - 14.0) 312 (15.7%) 6.1 (4.15), 5.0 (4.0 - 7.0) 
Western Europe 349 (18.3%) 12.9 (9.94), 10.0 (7.0 - 15.0) 21 (23.9%) 12.1 (9.96), 11.0 (5.0 - 15.0) 370 (18.6%) 12.9 (9.93), 10.0 (7.0 - 15.0) 
Eastern Europe 631 (33.2%) 10.3 (5.94), 8.0 (7.0 - 12.0) 38 (43.2%) 11.7 (8.77), 10.5 (5.0 - 16.0) 669 (33.6%) 10.4 (6.13), 8.0 (7.0 - 13.0) 
Argentina 52 (2.7%) 5.2 (3.12), 4.5 (4.0 - 6.0) 1 (1.1%) 2.0 (n.d.), 2.0 (2.0 - 2.0) 53 (2.7%) 5.2 (3.13), 4.0 (4.0 - 6.0) 
Russia 268 (14.1%) 17.4 (6.82), 16.0 (14.0 - 20.0) 15 (17.0%) 11.5 (14.17), 5.0 (4.0 - 14.0) 283 (14.2%) 17.0 (7.46), 15.0 (14.0 - 20.0) 
  
Overall 1902 (100%) 10.4 (7.60), 8.0 (6.0 - 14.0) 88 (100%) 12.3 (10.24), 10.5 (5.0 - 15.5) 1990 (100%) 10.5 (7.74), 8.0 (6.0 - 14.0) 
  
  
Notes: 
[1] Results shown are mean (standard deviation), median (25th - 75th percentile). 
 
  
Table 2a: Univariable and multivariable associations of baseline characteristics with length of stay 
 ------- Univariable model [1] ------- ------ Multivariable model [1] ------ 
Parameter 
Mean difference for a 
change of Mean difference (95% CI) P-value Mean difference (95% CI) P-value 
Age, y 10 -0.03 (-0.29, 0.24) 0.8417   
Male sex Yes vs. No -0.62 (-1.26, 0.02) 0.0563 -0.76 (-1.40, -0.12) 0.0193 
White race Yes vs. No 0.31 (-1.29, 1.90) 0.7056   
Time from presentation to rand., h 1 0.02 (0.00, 0.05) 0.0610   
Ischemic heart disease Yes vs. No 0.12 (-0.54, 0.79) 0.7144   
History of angina Yes vs. No 0.89 (0.12, 1.67) 0.0245 0.79 (0.03, 1.55) 0.0426 
Previous stroke or PVD Yes vs. No 0.03 (-0.74, 0.81) 0.9311   
Diabetes mellitus Yes vs. No 1.04 (0.44, 1.65) 0.0008 0.72 (0.09, 1.35) 0.0251 
Respiratory disease Yes vs. No 0.36 (-0.40, 1.12) 0.3525   
Mitral regurgitation Yes vs. No 0.18 (-0.46, 0.83) 0.5782   
History of atrial fibrillation/flutter Yes vs. No 0.35 (-0.26, 0.95) 0.2603   
History of CHF Yes vs. No -1.42 (-2.83, 0.00) 0.0499 -1.56 (-2.95, -0.17) 0.0284 
History of hypertension Yes vs. No 0.08 (-0.67, 0.83) 0.8337   
History of hyperlipidemia Yes vs. No -0.04 (-0.69, 0.61) 0.9039   
History of smoking Yes vs. No 0.24 (-0.52, 1.01) 0.5337   
History of CABG or PCI Yes vs. No -0.11 (-0.77, 0.56) 0.7579   
HF hospitalization in previous year Yes vs. No 0.61 (0.01, 1.21) 0.0473   
NYHA class in previous month None/I/II vs. III/IV 0.24 (-0.53, 1.01) 0.5369   
 ------- Univariable model [1] ------- ------ Multivariable model [1] ------ 
Parameter 
Mean difference for a 
change of Mean difference (95% CI) P-value Mean difference (95% CI) P-value 
BMI, kg/m**2 1 0.08 (0.04, 0.13) 0.0008 0.06 (0.01, 0.11) 0.0231 
Heart rate <=90 bpm [4] 5 -0.12 (-0.28, 0.03) 0.0618 -0.09 (-0.25, 0.06) 0.0072 
Heart rate >90 bpm [4] 5 0.43 (0.18, 0.69)  0.40 (0.15, 0.65)  
Systolic blood pressure, mmHg 10 -0.20 (-0.37, -0.02) 0.0268 -0.18 (-0.36, 0.01) 0.0578 
Diastolic blood pressure, mmHg 5 -0.12 (-0.25, 0.01) 0.0731   
Respiratory rate, breaths per min [3] 24.00 vs. 18.00 -0.53 (-1.10, 0.04) 0.0034   
Edema <=2 vs. >2 1.03 (0.39, 1.68) 0.0017   
JVP <=10 cm vs. >10 cm 0.95 (0.30, 1.59) 0.0043 0.78 (0.13, 1.43) 0.0194 
Orthopnea <=1 vs. >1 pillow 1.03 (0.21, 1.85) 0.0139 0.96 (0.14, 1.78) 0.0214 
Rales <1/3 vs. >=1/3 -0.03 (-0.67, 0.60) 0.9164   
Hemoglobin, g/dL 1 -0.25 (-0.41, -0.09) 0.0029   
WBC count, x10**9/L [2] 9.26 vs. 6.11 -0.20 (-0.59, 0.18) <.0001 -0.23 (-0.61, 0.15) 0.0002 
Sodium, mEq/L 3 -0.23 (-0.45, 0.00) 0.0519   
Potassium, mEq/L 1 0.35 (-0.20, 0.90) 0.2082   
Bicarbonate, mEq/L 1 -0.03 (-0.11, 0.05) 0.4989   
Creatinine, mg/dL 1 0.94 (0.40, 1.48) 0.0006   
BUN, mg/dL 1 0.05 (0.04, 0.07) <.0001 0.04 (0.02, 0.05) 0.0005 
Uric acid, mg/dL 10 0.04 (0.02, 0.06) <.0001 0.02 (0.00, 0.05) 0.0313 
Albumin, g/dL 1 -1.40 (-2.11, -0.68) 0.0001 -1.07 (-1.79, -0.35) 0.0036 
 ------- Univariable model [1] ------- ------ Multivariable model [1] ------ 
Parameter 
Mean difference for a 
change of Mean difference (95% CI) P-value Mean difference (95% CI) P-value 
ALT, U/L 1 0.01 (0.00, 0.02) 0.0650   
Glucose, mg/dL 1 0.08 (-0.02, 0.17) 0.1154   
Cholesterol <=4.5 mg/dL [4] 1 -1.07 (-1.51, -0.62) <.0001 -0.55 (-1.01, -0.10) 0.0552 
Cholesterol >4.5 mg/dL [4] 1 0.33 (-0.29, 0.94)  0.36 (-0.25, 0.97)  
Triglycerides, mg/dL 1 0.00 (-0.01, 0.00) 0.1688   
Observed adjusted R-squared    0.2805  
Bias-corrected adjusted R-squared (95% CI) 
[5] 
   0.2703 (0.2327, 0.3079)  
  
Notes: 
ALT, alanine aminotransferase; BMI, body mass index; BUN, blood urea nitrogen; CABG, coronary artery bypass graft; CHF, chronic heart failure; CI, 
confidence interval; eGFR, estimated glomerular filtration rate; HF, heart failure; JVP, jugular venous pressure; NYHA, New York Heart Association; PCI, 
percutaneous coronary intervention; PVD, peripheral vascular disease; WBC, white blood cells. 
[1] Results from linear regression model adjusted for region. 
[2] Non-linear association modeled as quadratic transformation. HR for the 75th vs. the 25th percentile is presented. 
[3] Non-linear association modeled as cubic transformation. HR for the 75th vs. the 25th percentile is presented. 
[4] Non-linear association modeled as linear spline. 
[5] Bootstrap estimate with 1000 resampling steps. 
 
  
Table 2b: Change in R-squared for model adjusted length of stay 
Model [1] 
Observed 
adjusted R-
squared 
Bias-corrected adjusted R-
squared (95% CI) [2] 
Bias-corrected difference 
in adjusted R-squared 
(95% CI), compared to 
model in first line [2] 
Adjusted for original predictors 0.2805 0.2703 (0.2327, 0.3079)  
Albumin (day 2 changes) 0.2879 0.2775 (0.2392, 0.3158) 0.0072 (0.0004, 0.0139) 
AST (day 2 changes and corresponding baseline values) 0.2850 0.2735 (0.2349, 0.3120) 0.0032 (-0.0036, 0.0100) 
Cholesterol (day 2 changes) 0.2907 0.2799 (0.2423, 0.3176) 0.0096 (0.0009, 0.0184) 
Creatinine (day 2 changes and corresponding baseline values) 0.2834 0.2723 (0.2341, 0.3105) 0.0020 (-0.0035, 0.0075) 
Weight (day 2 changes and corresponding baseline values) 0.2856 0.2741 (0.2360, 0.3123) 0.0038 (-0.0026, 0.0103) 
All day 2 changes and corresponding baseline values 0.2927 0.2782 (0.2402, 0.3161) 0.0079 (-0.0029, 0.0187) 
Worsening heart failure by day 7 0.3220 0.3119 (0.2747, 0.3491) 0.0416 (0.0214, 0.0619) 
All day 2 changes, corresponding baseline values, and worsening heart failure by day 
7 
0.3343 0.3204 (0.2840, 0.3568) 0.0501 (0.0282, 0.0719) 
  
Notes: 
AST, aspartate aminotransferase; CI, confidence interval. 
[1] Results from linear regression model adjusted for region. 
[2] Bootstrap estimate with 1000 resampling steps. 
 
  
Table 3a: Multivariable associations of baseline characteristics with rehospitalization up to 30 days after discharge 
 --- Multivariable model [1] --- 
Multivariable model 
including length of stay [1] 
Multivariable model 
including length of stay and 
worsening heart failure [1] 
Parameter OR for a change of OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value 
Diabetes mellitus Yes vs. No 1.25 (0.98, 1.59) 0.0675 1.24 (0.97, 1.58) 0.0811 1.24 (0.97, 1.57) 0.0830 
Edema <=2 vs. >2 0.80 (0.62, 1.03) 0.0788 0.78 (0.61, 1.00) 0.0545 0.78 (0.61, 1.00) 0.0545 
Orthopnea <=1 vs. >1 pillow 1.43 (1.02, 2.00) 0.0390 1.38 (0.99, 1.94) 0.0609 1.39 (0.99, 1.94) 0.0598 
BUN, mg/dL 1 1.02 (1.01, 1.02) <.0001 1.01 (1.01, 1.02) <.0001 1.01 (1.01, 1.02) <.0001 
Length of stay, days 1   1.02 (1.00, 1.05) 0.0525 1.02 (1.00, 1.05) 0.0888 
Worsening heart failure by day 7 Yes vs. No     1.10 (0.76, 1.60) 0.6215 
Observed C-statistic  0.6864  0.6871  0.6871  
Bias-corrected C-statistic (95% CI) [2]  0.6823 (0.6535, 
0.7110) 
 0.6821 (0.6531, 
0.7110) 
 0.6814 (0.6525, 
0.7103) 
 
Bias-corrected difference in C-statistics 
(95% CI), compared to model in previous 
column [2] 
   -0.0002 (-0.0051, 
0.0047) 
 -0.0007 (-0.0031, 
0.0017) 
 
Interaction test of length of stay with 
region 
    0.3269  0.3100 
  
Notes: 
BUN, blood urea nitrogen; CI, confidence interval; OR, odds ratio. 
[1] Results from logistic regression model stratified by region. C-
statistics computed based on logistic regression model adjusted for region (instead of stratification). 
[2] Bootstrap estimate with 1000 resampling steps. 
 
Table 3b: Multivariable associations of baseline characteristics with rehospitalizations for heart failure up to 30 days after 
discharge 
 --- Multivariable model [1] --- 
Multivariable model 
including length of stay [1] 
Multivariable model 
including length of stay and 
worsening heart failure [1] 
Parameter OR for a change of OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value 
HF hospitalization in previous year Yes vs. No 2.11 (1.50, 2.95) <.0001 2.10 (1.50, 2.95) <.0001 2.10 (1.50, 2.94) <.0001 
Orthopnea <=1 vs. >1 pillow 1.73 (1.06, 2.83) 0.0300 1.72 (1.05, 2.82) 0.0329 1.72 (1.05, 2.83) 0.0325 
Sodium, mEq/L 3 0.82 (0.73, 0.91) 0.0005 0.82 (0.73, 0.91) 0.0005 0.81 (0.73, 0.91) 0.0005 
BUN, mg/dL 1 1.02 (1.01, 1.03) <.0001 1.02 (1.01, 1.03) <.0001 1.02 (1.01, 1.03) <.0001 
Albumin, g/dL 1 1.52 (1.03, 2.24) 0.0346 1.53 (1.03, 2.26) 0.0336 1.53 (1.04, 2.26) 0.0330 
Length of stay, days 1   1.00 (0.97, 1.04) 0.8152 1.00 (0.97, 1.04) 0.9312 
Worsening heart failure by day 7 Yes vs. No     1.11 (0.67, 1.83) 0.6845 
Observed C-statistic  0.7462  0.7457  0.7462  
Bias-corrected C-statistic (95% CI) [2]  0.7397 (0.7042, 
0.7752) 
 0.7385 (0.7029, 
0.7741) 
 0.7385 (0.7028, 
0.7743) 
 
Bias-corrected difference in C-statistics 
(95% CI), compared to model in previous 
column [2] 
   -0.0012 (-0.0037, 
0.0013) 
 0.0000 (-0.0028, 
0.0029) 
 
 --- Multivariable model [1] --- 
Multivariable model 
including length of stay [1] 
Multivariable model 
including length of stay and 
worsening heart failure [1] 
Parameter OR for a change of OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value 
Interaction test of length of stay with 
region 
    0.0499  0.0460 
  
Notes: 
BUN, blood urea nitrogen; CI, confidence interval; HF, heart failure; OR, odds ratio. 
[1] Results from logistic regression model stratified by region. C-
statistics computed based on logistic regression model adjusted for region (instead of stratification). 
[2] Bootstrap estimate with 1000 resampling steps. 
  
Table 4: Multivariable associations of baseline characteristics with death up to 90 days after discharge 
 --- Multivariable model [1] --- 
Multivariable model 
including length of stay [1] 
Multivariable model 
including length of stay and 
worsening heart failure [1] 
Parameter HR for a change of HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Age, y 10 1.28 (1.09, 1.50) 0.0022 1.29 (1.10, 1.52) 0.0016 1.30 (1.11, 1.52) 0.0014 
Respiratory disease Yes vs. No 1.57 (1.09, 2.26) 0.0144 1.63 (1.14, 2.34) 0.0082 1.61 (1.12, 2.31) 0.0097 
Systolic blood pressure, mmHg 10 0.83 (0.74, 0.92) 0.0005 0.83 (0.75, 0.92) 0.0006 0.83 (0.75, 0.93) 0.0008 
WBC count, x10**9/L 5 1.20 (1.00, 1.43) 0.0522 1.16 (0.97, 1.38) 0.1072 1.17 (0.98, 1.40) 0.0895 
Sodium, mEq/L 3 0.82 (0.73, 0.92) 0.0008 0.83 (0.74, 0.93) 0.0015 0.83 (0.74, 0.93) 0.0012 
Bicarbonate <=24 mEq/L [2] 1 0.88 (0.82, 0.95) 0.0035 0.88 (0.82, 0.96) 0.0044 0.88 (0.82, 0.95) 0.0043 
Bicarbonate >24 mEq/L [2] 1 1.09 (1.01, 1.17)  1.08 (1.00, 1.16)  1.08 (1.00, 1.16)  
BUN, mg/dL (log2) Doubling 1.63 (1.22, 2.16) 0.0008 1.54 (1.16, 2.05) 0.0033 1.52 (1.14, 2.03) 0.0044 
Uric acid, mg/dL 10 1.01 (1.00, 1.02) 0.0366 1.01 (1.00, 1.02) 0.0489 1.01 (1.00, 1.02) 0.0553 
Length of stay <=14 days [2] 1   1.11 (1.05, 1.17) 0.0003 1.10 (1.04, 1.16) 0.0030 
Length of stay >14 days [2] 1   0.99 (0.96, 1.02)  0.99 (0.96, 1.02)  
Worsening heart failure by day 7 Yes vs. No     1.35 (0.88, 2.06) 0.1680 
Observed C-statistic  0.7324  0.7411  0.7443  
Bias-corrected C-statistic (95% CI) [3]  0.7263 (0.6881, 
0.7646) 
 0.7348 (0.6961, 
0.7735) 
 0.7377 (0.6989, 
0.7764) 
 
Bias-corrected difference in C-statistics 
(95% CI), compared to model in previous 
column [3] 
   0.0085 (-0.0065, 
0.0234) 
 0.0029 (-0.0043, 
0.0100) 
 
 --- Multivariable model [1] --- 
Multivariable model 
including length of stay [1] 
Multivariable model 
including length of stay and 
worsening heart failure [1] 
Parameter HR for a change of HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Interaction test of length of stay with 
region 
    0.1093  0.1169 
  
Notes: 
BUN, blood urea nitrogen; CI, confidence interval; HR, hazard ratio; NYHA, New York Heart Association; WBC, white blood cells. 
[1] Results from Cox proportional hazards model stratified by region. 
[2] Non-linear association modeled as linear spline. 
[3] Bootstrap estimate with 1000 resampling steps. 
 
  
Table 5: Model adjusted associations of length of stay with death up to 90 days after discharge 
 
 -------------------- Length of stay [2] -------------------- 
Model [1] 
LOS <=14 days 
HR (95% CI) 
LOS >14 days 
HR (95% CI) P-value 
Adjusted for original predictors 1.11 (1.05, 1.17) 0.99 (0.96, 1.02) 0.0003 
Albumin (day 2 changes and corresponding baseline values) 1.12 (1.06, 1.18) 0.99 (0.96, 1.02) 0.0001 
AST (day 2 changes and corresponding baseline values) 1.12 (1.06, 1.17) 0.99 (0.96, 1.02) <.0001 
Cholesterol (day 2 changes and corresponding baseline values) 1.11 (1.05, 1.17) 0.99 (0.96, 1.02) 0.0003 
Creatinine (day 2 changes and corresponding baseline values) 1.11 (1.06, 1.17) 0.99 (0.96, 1.02) 0.0001 
Weight (day 2 changes and corresponding baseline values) 1.11 (1.06, 1.17) 0.99 (0.96, 1.02) 0.0002 
All day 2 changes and corresponding baseline values 1.10 (1.05, 1.16) 0.99 (0.96, 1.02) 0.0009 
Worsening heart failure by day 7 1.10 (1.04, 1.16) 0.99 (0.96, 1.02) 0.0030 
All day 2 changes, corresponding baseline values, and worsening heart failure by day 7 1.10 (1.04, 1.16) 0.99 (0.96, 1.02) 0.0043 
  
Notes: 
CI, confidence interval; HR, hazard ratio; LOS, length of stay. 
[1] Results from Cox proportional hazards model including length of stay and stratified by region. For each lab change the corresponding baseline values 
have been included into the model if they were not already among the set of original predictors. 
[2] Non-linear association modeled as linear spline. Hazard ratio presented for a change of one day. 
 
  
Figure 1: Rate of heart failure readmissions after discharge during the first 30 days post discharge 
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Figure 2: HF Readmission over 30 days in patients with and without previous HF admission prior to the study related admission 
 
 
  
Supplementary table 1: Baseline characteristics by length of stay categories 
 
------------------------------------------------ Length of stay [1] ------------------------------------------
------  
Parameter 
n (% 
missing) Category Short (N = 852) Medium (N = 484) Long (N = 566) 
P-value 
[2] 
Age, y 1902 (0.0%)  69.6 (11.96), 71.0 (61.0 - 
79.0) 
70.8 (11.39), 73.0 (64.0 - 
79.0) 
69.8 (11.38), 71.0 (62.0 - 
78.0) 
0.1792 
Male sex 1902 (0.0%)  592 (69.5%) 318 (65.7%) 365 (64.5%) 0.1129 
White race 1889 (0.7%)  802 (95.0%) 450 (93.9%) 546 (96.5%) 0.1589 
Time from presentation to 
rand., h 
1885 (0.9%)  14.0 (8.17), 16.2 (5.2 - 21.4) 15.5 (18.80), 17.5 (6.0 - 
21.8) 
15.6 (12.57), 17.8 (6.6 - 
22.2) 
0.0355 
Ischemic heart disease 1900 (0.1%)  581 (68.3%) 331 (68.4%) 399 (70.6%) 0.6102 
History of angina 1898 (0.2%)  164 (19.3%) 94 (19.5%) 155 (27.4%) 0.0006 
Previous stroke or PVD 1902 (0.0%)  146 (17.1%) 92 (19.0%) 111 (19.6%) 0.4541 
Diabetes mellitus 1901 (0.1%)  352 (41.3%) 239 (49.4%) 281 (49.7%) 0.0016 
Respiratory disease 1898 (0.2%)  168 (19.8%) 85 (17.6%) 124 (21.9%) 0.2236 
Mitral regurgitation 1899 (0.2%)  281 (33.0%) 169 (34.9%) 194 (34.4%) 0.7484 
History of atrial 
fibrillation/flutter 
1888 (0.7%)  446 (52.7%) 249 (51.8%) 318 (56.7%) 0.2167 
History of CHF 1902 (0.0%)  809 (95.0%) 461 (95.2%) 536 (94.7%) 0.9214 
History of hypertension 1902 (0.0%)  666 (78.2%) 391 (80.8%) 457 (80.7%) 0.3776 
History of hyperlipidemia 1901 (0.1%)  453 (53.2%) 247 (51.1%) 302 (53.4%) 0.7242 
History of smoking 1898 (0.2%)  179 (21.1%) 98 (20.3%) 119 (21.1%) 0.9374 
 
------------------------------------------------ Length of stay [1] ------------------------------------------
------  
Parameter 
n (% 
missing) Category Short (N = 852) Medium (N = 484) Long (N = 566) 
P-value 
[2] 
History of CABG or PCI 1892 (0.5%)  325 (38.4%) 186 (38.5%) 217 (38.6%) 0.9957 
HF hospitalization in previous 
year 
1902 (0.0%)  397 (46.6%) 232 (47.9%) 298 (52.7%) 0.0759 
NYHA class in previous 
month 
1900 (0.1%) None/I/II 190 (22.3%) 112 (23.1%) 118 (20.9%) 0.1453 
  III 431 (50.6%) 229 (47.3%) 258 (45.7%)  
  IV 231 (27.1%) 143 (29.5%) 188 (33.3%)  
BMI, kg/m**2 1880 (1.2%)  28.36 (5.926), 27.36 (24.12 
- 31.23) 
28.94 (5.974), 27.91 (24.75 
- 31.77) 
29.44 (6.560), 28.37 (24.68 
- 32.87) 
0.0050 
Heart rate, bpm 1900 (0.1%)  79.9 (14.58), 80.0 (70.0 - 
90.0) 
79.8 (15.65), 78.0 (69.0 - 
90.0) 
80.7 (16.47), 78.0 (69.0 - 
90.0) 
0.5562 
Systolic blood pressure, 
mmHg 
1902 (0.0%)  124.7 (16.71), 125.0 (110.0 
- 140.0) 
127.0 (17.91), 130.0 (110.0 
- 140.0) 
122.9 (18.02), 120.0 (110.0 
- 137.0) 
0.0008 
Diastolic blood pressure, 
mmHg 
1902 (0.0%)  74.2 (11.65), 73.0 (68.0 - 
80.0) 
74.2 (12.21), 74.0 (65.0 - 
80.0) 
73.2 (11.81), 72.0 (65.0 - 
80.0) 
0.2618 
Pulse pressure, mmHg 1902 (0.0%)  50.5 (14.41), 50.0 (40.0 - 
60.0) 
52.8 (15.04), 50.0 (40.0 - 
60.0) 
49.7 (15.80), 49.0 (40.0 - 
60.0) 
0.0028 
Mean arterial pressure, 
mmHg 
1902 (0.0%)  91.02 (11.723), 90.00 
(83.33 - 99.00) 
91.79 (12.487), 91.83 
(82.17 - 100.00) 
89.77 (12.075), 90.00 
(80.00 - 98.00) 
0.0218 
Respiratory rate, breaths per 
min 
1813 (4.7%)  21.2 (4.23), 21.0 (18.0 - 
24.0) 
21.1 (4.01), 20.0 (18.0 - 
24.0) 
21.3 (4.34), 20.0 (18.0 - 
24.0) 
0.5655 
Edema 1902 (0.0%) 0 139 (16.3%) 70 (14.5%) 66 (11.7%) <.0001 
 
------------------------------------------------ Length of stay [1] ------------------------------------------
------  
Parameter 
n (% 
missing) Category Short (N = 852) Medium (N = 484) Long (N = 566) 
P-value 
[2] 
  >1 189 (22.2%) 70 (14.5%) 91 (16.1%)  
  >2 358 (42.0%) 213 (44.0%) 198 (35.0%)  
  >3 166 (19.5%) 131 (27.1%) 211 (37.3%)  
JVP 1717 (9.7%) <6 cm 89 (11.8%) 48 (10.9%) 67 (12.9%) 0.0278 
  6-10 cm 390 (51.5%) 212 (48.2%) 221 (42.5%)  
  >10 cm 278 (36.7%) 180 (40.9%) 232 (44.6%)  
Orthopnea 1877 (1.3%) None 36 (4.3%) 20 (4.2%) 20 (3.6%) <.0001 
  1 pillow 124 (14.8%) 55 (11.5%) 48 (8.5%)  
  2 pillows 365 (43.7%) 184 (38.5%) 214 (38.0%)  
  >30° 311 (37.2%) 219 (45.8%) 281 (49.9%)  
Rales 1899 (0.2%) 0 84 (9.9%) 46 (9.5%) 52 (9.2%) 0.0050 
  <1/3 245 (28.8%) 160 (33.1%) 159 (28.1%)  
  1/3 to 2/3 461 (54.2%) 227 (47.0%) 282 (49.8%)  
  >2/3 60 (7.1%) 50 (10.4%) 73 (12.9%)  
Hemoglobin, g/dL 1662 
(12.6%) 
 12.87 (1.908), 12.80 (11.50 
- 14.15) 
12.58 (1.967), 12.50 (11.20 
- 13.90) 
12.52 (2.067), 12.40 (11.00 
- 13.80) 
0.0045 
WBC count, x10**9/L 1662 
(12.6%) 
 7.83 (2.663), 7.44 (6.22 - 
9.04) 
7.90 (2.853), 7.48 (5.92 - 
9.31) 
8.08 (3.928), 7.41 (6.01 - 
9.29) 
0.3715 
Sodium, mEq/L 1846 (2.9%)  139.5 (3.86), 140.0 (137.0 - 
142.0) 
139.5 (4.08), 140.0 (137.0 - 
142.0) 
139.1 (4.27), 140.0 (137.0 - 
142.0) 
0.1300 
 
------------------------------------------------ Length of stay [1] ------------------------------------------
------  
Parameter 
n (% 
missing) Category Short (N = 852) Medium (N = 484) Long (N = 566) 
P-value 
[2] 
Potassium, mEq/L 1750 (8.0%)  4.27 (0.573), 4.20 (3.90 - 
4.60) 
4.27 (0.588), 4.20 (3.90 - 
4.70) 
4.28 (0.564), 4.20 (3.90 - 
4.60) 
0.9100 
Bicarbonate, mEq/L 1771 (6.9%)  24.0 (3.64), 24.0 (21.0 - 
26.0) 
24.1 (3.71), 24.0 (22.0 - 
26.0) 
23.9 (4.00), 24.0 (21.0 - 
26.0) 
0.6478 
Creatinine, mg/dL 1843 (3.1%)  1.47 (0.547), 1.30 (1.10 - 
1.70) 
1.53 (0.616), 1.40 (1.10 - 
1.80) 
1.54 (0.577), 1.40 (1.20 - 
1.80) 
0.0262 
eGFR, mL/min 1840 (3.3%)  50.49 (18.805), 48.64 
(36.86 - 61.76) 
48.15 (19.236), 45.10 
(32.77 - 60.40) 
46.69 (17.489), 44.29 
(34.04 - 56.50) 
0.0007 
BUN, mg/dL 1848 (2.8%)  31.8 (15.76), 28.0 (21.0 - 
38.0) 
33.3 (16.53), 29.0 (22.0 - 
41.5) 
36.0 (18.89), 31.0 (23.0 - 
43.0) 
<.0001 
BUN/creatinine ratio 1843 (3.1%)  21.76 (6.686), 20.61 (17.27 
- 25.00) 
21.88 (6.980), 20.77 (17.14 
- 25.45) 
23.28 (7.527), 22.00 (17.78 
- 27.69) 
0.0002 
Uric acid, mg/dL 1771 (6.9%)  517.76 (144.986), 505.58 
(422.31 - 612.64) 
527.57 (151.302), 523.42 
(410.41 - 630.49) 
559.71 (156.333), 544.24 
(452.05 - 660.23) 
<.0001 
Albumin, g/dL 1842 (3.2%)  3.93 (0.408), 3.90 (3.70 - 
4.20) 
3.79 (0.458), 3.80 (3.60 - 
4.10) 
3.81 (0.421), 3.80 (3.50 - 
4.10) 
<.0001 
ALT, U/L 1721 (9.5%)  27.2 (24.71), 21.0 (15.0 - 
30.0) 
29.0 (27.58), 21.0 (15.0 - 
33.0) 
33.3 (39.15), 21.0 (15.0 - 
33.0) 
0.0021 
Glucose, mg/dL 1787 (6.0%)  7.79 (3.168), 6.99 (5.72 - 
8.88) 
7.88 (3.397), 7.10 (5.61 - 
9.21) 
7.87 (3.195), 7.10 (5.77 - 
9.10) 
0.8774 
Cholesterol, mg/dL 1841 (3.2%)  3.96 (1.087), 3.88 (3.19 - 
4.64) 
3.85 (1.178), 3.65 (3.08 - 
4.43) 
3.64 (1.143), 3.47 (2.80 - 
4.27) 
<.0001 
 
------------------------------------------------ Length of stay [1] ------------------------------------------
------  
Parameter 
n (% 
missing) Category Short (N = 852) Medium (N = 484) Long (N = 566) 
P-value 
[2] 
Triglycerides, mg/dL 1829 (3.8%)  104.7 (53.19), 94.0 (67.0 - 
128.0) 
100.6 (51.96), 88.5 (65.0 - 
120.0) 
97.6 (49.91), 84.5 (64.0 - 
119.0) 
0.0423 
  
Notes: 
ALT, alanine transferase; BMI, body mass index; BUN, blood urea nitrogen; CABG, coronary artery bypass graft; CHF, chronic heart failure; eGFR, estimated 
glomerular filtration rate; HF, heart failure; JVP, jugular venous pressure; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; PVD, 
peripheral vascular disease; WBC, white blood cells. 
[1] Results shown are mean (standard deviation), median (25th - 75th percentile) for continuous variables, or prevalence (%) for categorical variables, unless 
otherwise noted. Numbers may vary due to missing values. 
[2] P-values from ANOVA (F-test) for continuous variables, or from Chi-squared test for categorical variables, unless otherwise noted. 
 
  
Supplemental table 2a: Baseline characteristics by rehospitalization up to 30 days after discharge 
 
------------------ Any cause rehospitalization up to 30 days after discharge [1] ---------
---------  
Parameter 
n (% 
missing) Category No (N = 1477) Yes (N = 372) P-value [2] 
Age, y 1849 (0.0%)  69.8 (11.47), 71.0 (62.0 - 78.0) 70.5 (12.38), 73.0 (62.5 - 80.0) 0.2744 
Male sex 1849 (0.0%)  988 (66.9%) 254 (68.3%) 0.6106 
White race 1836 (0.7%)  1399 (95.4%) 347 (94.0%) 0.2914 
Time from presentation to rand., 
h 
1834 (0.8%)  14.9 (13.97), 17.1 (5.5 - 21.6) 14.3 (8.23), 16.5 (5.6 - 21.8) 0.4394 
Ischemic heart disease 1847 (0.1%)  1005 (68.1%) 268 (72.0%) 0.1456 
History of angina 1845 (0.2%)  326 (22.1%) 68 (18.4%) 0.1251 
Previous stroke or PVD 1849 (0.0%)  267 (18.1%) 77 (20.7%) 0.2455 
Diabetes mellitus 1848 (0.1%)  643 (43.6%) 201 (54.0%) 0.0003 
Respiratory disease 1845 (0.2%)  281 (19.0%) 78 (21.1%) 0.3620 
Mitral regurgitation 1846 (0.2%)  498 (33.8%) 126 (33.9%) 0.9752 
History of atrial 
fibrillation/flutter 
1836 (0.7%)  789 (53.8%) 194 (52.4%) 0.6325 
History of CHF 1849 (0.0%)  1401 (94.9%) 358 (96.2%) 0.2682 
History of hypertension 1849 (0.0%)  1176 (79.6%) 298 (80.1%) 0.8347 
History of hyperlipidemia 1848 (0.1%)  742 (50.3%) 239 (64.2%) <.0001 
History of smoking 1845 (0.2%)  300 (20.4%) 82 (22.1%) 0.4572 
History of CABG or PCI 1839 (0.5%)  531 (36.2%) 185 (49.9%) <.0001 
 
------------------ Any cause rehospitalization up to 30 days after discharge [1] ---------
---------  
Parameter 
n (% 
missing) Category No (N = 1477) Yes (N = 372) P-value [2] 
HF hospitalization in previous 
year 
1849 (0.0%)  684 (46.3%) 216 (58.1%) <.0001 
NYHA class in previous month 1847 (0.1%) None/I/II 319 (21.6%) 89 (23.9%) 0.0002 
  III 692 (46.9%) 206 (55.4%)  
  IV 464 (31.5%) 77 (20.7%)  
BMI, kg/m**2 1827 (1.2%)  28.74 (6.192), 27.64 (24.34 - 31.64) 29.08 (5.931), 28.20 (24.69 - 32.31) 0.3417 
Heart rate, bpm 1847 (0.1%)  80.8 (15.68), 80.0 (70.0 - 90.0) 77.1 (13.71), 76.0 (68.0 - 85.0) <.0001 
Systolic blood pressure, mmHg 1849 (0.0%)  125.4 (17.36), 125.0 (110.0 - 140.0) 122.4 (17.46), 120.0 (110.0 - 136.0) 0.0029 
Diastolic blood pressure, mmHg 1849 (0.0%)  74.6 (11.78), 75.0 (68.0 - 80.0) 71.5 (11.84), 70.0 (62.0 - 80.0) <.0001 
Pulse pressure, mmHg 1849 (0.0%)  50.8 (14.92), 50.0 (40.0 - 60.0) 50.9 (15.54), 50.0 (40.0 - 60.0) 0.9137 
Mean arterial pressure, mmHg 1849 (0.0%)  91.50 (11.976), 91.67 (83.33 - 100.00) 88.43 (11.895), 87.33 (80.00 - 96.67) <.0001 
Respiratory rate, breaths per 
min 
1766 (4.5%)  21.2 (4.22), 21.0 (18.0 - 24.0) 21.0 (4.04), 20.0 (18.0 - 24.0) 0.2999 
Edema 1849 (0.0%) 0 202 (13.7%) 70 (18.8%) 0.0089 
  >1 264 (17.9%) 72 (19.4%)  
  >2 603 (40.8%) 154 (41.4%)  
  >3 408 (27.6%) 76 (20.4%)  
JVP 1672 (9.6%) <6 cm 158 (11.9%) 42 (12.4%) 0.8598 
  6-10 cm 645 (48.4%) 159 (46.8%)  
 
------------------ Any cause rehospitalization up to 30 days after discharge [1] ---------
---------  
Parameter 
n (% 
missing) Category No (N = 1477) Yes (N = 372) P-value [2] 
  >10 cm 529 (39.7%) 139 (40.9%)  
Orthopnea 1824 (1.4%) None 57 (3.9%) 14 (3.8%) 0.7731 
  1 pillow 181 (12.4%) 39 (10.7%)  
  2 pillows 591 (40.5%) 156 (42.9%)  
  >30° 631 (43.2%) 155 (42.6%)  
Rales 1846 (0.2%) 0 144 (9.8%) 33 (8.9%) 0.7756 
  <1/3 430 (29.2%) 116 (31.2%)  
  1/3 to 2/3 762 (51.7%) 185 (49.7%)  
  >2/3 138 (9.4%) 38 (10.2%)  
Hemoglobin, g/dL 1613 
(12.8%) 
 12.79 (1.980), 12.80 (11.40 - 14.10) 12.37 (1.901), 12.20 (11.10 - 13.70) 0.0006 
WBC count, x10**9/L 1613 
(12.8%) 
 7.88 (2.923), 7.42 (6.08 - 9.15) 7.97 (3.025), 7.49 (6.11 - 9.24) 0.6390 
Sodium, mEq/L 1793 (3.0%)  139.6 (3.92), 140.0 (137.0 - 142.0) 138.7 (4.30), 139.0 (136.0 - 142.0) <.0001 
Potassium, mEq/L 1702 (8.0%)  4.26 (0.580), 4.20 (3.90 - 4.60) 4.28 (0.541), 4.25 (3.90 - 4.60) 0.6735 
Bicarbonate, mEq/L 1720 (7.0%)  24.0 (3.75), 24.0 (21.0 - 26.0) 24.0 (3.80), 24.0 (22.0 - 27.0) 0.8856 
Creatinine, mg/dL 1790 (3.2%)  1.47 (0.557), 1.30 (1.10 - 1.70) 1.62 (0.596), 1.50 (1.20 - 1.90) <.0001 
eGFR, mL/min 1787 (3.4%)  49.72 (18.526), 48.28 (36.30 - 60.71) 45.57 (18.640), 42.92 (31.62 - 57.55) 0.0001 
BUN, mg/dL 1795 (2.9%)  31.9 (15.67), 28.0 (21.0 - 38.0) 38.4 (19.80), 33.5 (24.5 - 48.0) <.0001 
 
------------------ Any cause rehospitalization up to 30 days after discharge [1] ---------
---------  
Parameter 
n (% 
missing) Category No (N = 1477) Yes (N = 372) P-value [2] 
BUN/creatinine ratio 1790 (3.2%)  21.80 (6.931), 20.71 (17.00 - 25.00) 23.50 (7.210), 22.18 (18.15 - 27.89) <.0001 
Uric acid, mg/dL 1720 (7.0%)  527.18 (149.330), 517.48 (422.31 - 
624.54) 
549.04 (151.685), 529.37 (440.15 - 
648.33) 
0.0155 
Albumin, g/dL 1789 (3.2%)  3.85 (0.432), 3.90 (3.60 - 4.10) 3.88 (0.422), 3.90 (3.60 - 4.10) 0.3388 
ALT, U/L 1673 (9.5%)  29.6 (29.93), 21.0 (15.0 - 32.0) 28.6 (31.36), 19.0 (14.0 - 29.0) 0.5868 
Glucose, mg/dL 1737 (6.1%)  7.77 (3.210), 6.99 (5.61 - 8.88) 8.00 (3.231), 7.10 (5.77 - 9.60) 0.2323 
Cholesterol, mg/dL 1788 (3.3%)  3.87 (1.138), 3.73 (3.08 - 4.53) 3.70 (1.101), 3.55 (2.93 - 4.31) 0.0089 
Triglycerides, mg/dL 1776 (3.9%)  100.7 (51.28), 89.0 (65.0 - 122.0) 105.7 (55.79), 95.0 (65.0 - 133.0) 0.1107 
  
Notes: 
ALT, alanine transferase; BMI, body mass index; BUN, blood urea nitrogen; CABG, coronary artery bypass graft; CHF, chronic heart failure; eGFR, estimated 
glomerular filtration rate; HF, heart failure; JVP, jugular venous pressure; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; PVD, 
peripheral vascular disease; WBC, white blood cells. 
[1] Results shown are mean (standard deviation), median (25th - 75th percentile) for continuous variables, or prevalence (%) for categorical variables, unless 
otherwise noted. Numbers may vary due to missing values. 
[2] P-values from ANOVA (F-test) for continuous variables, or from Chi-squared test for categorical variables, unless otherwise noted. 
 
 
  
Supplemental table 2b: Baseline characteristics by rehospitalization for heart failure up to 30 days after discharge 
 
----------------- Heart failure rehospitalization up to 30 days after discharge [1] ------
-----------  
Parameter 
n (% 
missing) Category No (N = 1667) Yes (N = 182) P-value [2] 
Age, y 1849 (0.0%)  69.9 (11.60), 72.0 (62.0 - 78.0) 70.0 (12.21), 73.0 (62.0 - 79.0) 0.9541 
Male sex 1849 (0.0%)  1116 (66.9%) 126 (69.2%) 0.5332 
White race 1836 (0.7%)  1580 (95.4%) 166 (92.7%) 0.1236 
Time from presentation to rand., 
h 
1834 (0.8%)  14.8 (13.46), 17.0 (5.5 - 21.6) 14.9 (8.10), 17.0 (6.4 - 22.1) 0.9456 
Ischemic heart disease 1847 (0.1%)  1144 (68.7%) 129 (70.9%) 0.5480 
History of angina 1845 (0.2%)  365 (21.9%) 29 (16.1%) 0.0707 
Previous stroke or PVD 1849 (0.0%)  310 (18.6%) 34 (18.7%) 0.9777 
Diabetes mellitus 1848 (0.1%)  743 (44.6%) 101 (55.5%) 0.0051 
Respiratory disease 1845 (0.2%)  318 (19.1%) 41 (22.9%) 0.2202 
Mitral regurgitation 1846 (0.2%)  552 (33.2%) 72 (39.6%) 0.0837 
History of atrial 
fibrillation/flutter 
1836 (0.7%)  883 (53.3%) 100 (55.6%) 0.5681 
History of CHF 1849 (0.0%)  1583 (95.0%) 176 (96.7%) 0.2997 
History of hypertension 1849 (0.0%)  1326 (79.5%) 148 (81.3%) 0.5718 
History of hyperlipidemia 1848 (0.1%)  861 (51.7%) 120 (65.9%) 0.0003 
History of smoking 1845 (0.2%)  340 (20.4%) 42 (23.2%) 0.3821 
History of CABG or PCI 1839 (0.5%)  626 (37.8%) 90 (49.5%) 0.0022 
 
----------------- Heart failure rehospitalization up to 30 days after discharge [1] ------
-----------  
Parameter 
n (% 
missing) Category No (N = 1667) Yes (N = 182) P-value [2] 
HF hospitalization in previous 
year 
1849 (0.0%)  778 (46.7%) 122 (67.0%) <.0001 
NYHA class in previous month 1847 (0.1%) None/I/II 368 (22.1%) 40 (22.0%) 0.0193 
  III 794 (47.7%) 104 (57.1%)  
  IV 503 (30.2%) 38 (20.9%)  
BMI, kg/m**2 1827 (1.2%)  28.77 (6.142), 27.68 (24.39 - 31.77) 29.09 (6.131), 28.39 (24.53 - 31.89) 0.5121 
Heart rate, bpm 1847 (0.1%)  80.4 (15.56), 79.0 (70.0 - 90.0) 76.8 (13.06), 76.0 (70.0 - 83.0) 0.0029 
Systolic blood pressure, mmHg 1849 (0.0%)  125.2 (17.32), 125.0 (110.0 - 140.0) 120.7 (17.78), 120.0 (107.0 - 135.0) 0.0007 
Diastolic blood pressure, mmHg 1849 (0.0%)  74.3 (11.81), 75.0 (67.0 - 80.0) 71.0 (11.84), 70.0 (61.0 - 80.0) 0.0005 
Pulse pressure, mmHg 1849 (0.0%)  51.0 (15.03), 50.0 (40.0 - 60.0) 49.6 (15.17), 49.0 (40.0 - 60.0) 0.2526 
Mean arterial pressure, mmHg 1849 (0.0%)  91.25 (11.953), 90.67 (83.33 - 100.00) 87.56 (12.154), 86.33 (78.00 - 96.00) <.0001 
Respiratory rate, breaths per 
min 
1766 (4.5%)  21.2 (4.18), 21.0 (18.0 - 24.0) 21.1 (4.23), 20.0 (18.0 - 24.0) 0.7683 
Edema 1849 (0.0%) 0 238 (14.3%) 34 (18.7%) 0.2111 
  >1 299 (17.9%) 37 (20.3%)  
  >2 685 (41.1%) 72 (39.6%)  
  >3 445 (26.7%) 39 (21.4%)  
JVP 1672 (9.6%) <6 cm 179 (11.9%) 21 (12.5%) 0.1411 
  6-10 cm 735 (48.9%) 69 (41.1%)  
 
----------------- Heart failure rehospitalization up to 30 days after discharge [1] ------
-----------  
Parameter 
n (% 
missing) Category No (N = 1667) Yes (N = 182) P-value [2] 
  >10 cm 590 (39.2%) 78 (46.4%)  
Orthopnea 1824 (1.4%) None 62 (3.8%) 9 (5.1%) 0.1959 
  1 pillow 207 (12.6%) 13 (7.3%)  
  2 pillows 673 (40.9%) 74 (41.8%)  
  >30° 705 (42.8%) 81 (45.8%)  
Rales 1846 (0.2%) 0 159 (9.6%) 18 (9.9%) 0.9466 
  <1/3 489 (29.4%) 57 (31.3%)  
  1/3 to 2/3 857 (51.5%) 90 (49.5%)  
  >2/3 159 (9.6%) 17 (9.3%)  
Hemoglobin, g/dL 1613 
(12.8%) 
 12.75 (1.970), 12.70 (11.30 - 14.10) 12.29 (1.940), 12.00 (10.95 - 13.60) 0.0063 
WBC count, x10**9/L 1613 
(12.8%) 
 7.87 (2.877), 7.42 (6.08 - 9.16) 8.21 (3.528), 7.56 (6.14 - 9.26) 0.1688 
Sodium, mEq/L 1793 (3.0%)  139.6 (3.89), 140.0 (137.0 - 142.0) 137.8 (4.75), 138.0 (135.0 - 141.0) <.0001 
Potassium, mEq/L 1702 (8.0%)  4.26 (0.576), 4.20 (3.80 - 4.60) 4.31 (0.540), 4.30 (3.90 - 4.60) 0.3281 
Bicarbonate, mEq/L 1720 (7.0%)  24.0 (3.72), 24.0 (22.0 - 26.0) 23.8 (4.12), 24.0 (21.0 - 27.0) 0.5217 
Creatinine, mg/dL 1790 (3.2%)  1.48 (0.561), 1.30 (1.10 - 1.70) 1.70 (0.597), 1.60 (1.20 - 2.10) <.0001 
eGFR, mL/min 1787 (3.4%)  49.51 (18.612), 47.74 (36.09 - 60.58) 43.21 (17.752), 39.07 (29.74 - 54.05) <.0001 
BUN, mg/dL 1795 (2.9%)  32.2 (15.85), 28.0 (21.0 - 39.0) 42.3 (21.68), 36.0 (26.0 - 51.0) <.0001 
 
----------------- Heart failure rehospitalization up to 30 days after discharge [1] ------
-----------  
Parameter 
n (% 
missing) Category No (N = 1667) Yes (N = 182) P-value [2] 
BUN/creatinine ratio 1790 (3.2%)  21.86 (6.842), 20.77 (17.14 - 25.26) 24.74 (8.019), 23.00 (18.75 - 30.00) <.0001 
Uric acid, mg/dL 1720 (7.0%)  527.23 (147.803), 517.48 (422.31 - 
624.54) 
572.68 (164.483), 553.16 (449.07 - 
689.97) 
0.0002 
Albumin, g/dL 1789 (3.2%)  3.85 (0.429), 3.90 (3.60 - 4.10) 3.90 (0.431), 3.90 (3.60 - 4.20) 0.1515 
ALT, U/L 1673 (9.5%)  29.4 (30.16), 21.0 (15.0 - 32.0) 28.8 (30.84), 20.0 (14.0 - 30.0) 0.8068 
Glucose, mg/dL 1737 (6.1%)  7.77 (3.186), 6.99 (5.66 - 8.99) 8.26 (3.438), 7.44 (5.88 - 9.88) 0.0543 
Cholesterol, mg/dL 1788 (3.3%)  3.87 (1.146), 3.73 (3.08 - 4.53) 3.55 (0.958), 3.37 (2.95 - 4.14) 0.0004 
Triglycerides, mg/dL 1776 (3.9%)  101.2 (51.67), 89.0 (65.0 - 124.0) 106.5 (57.06), 96.0 (67.0 - 131.0) 0.1980 
  
Notes: 
ALT, alanine transferase; BMI, body mass index; BUN, blood urea nitrogen; CABG, coronary artery bypass graft; CHF, chronic heart failure; eGFR, estimated 
glomerular filtration rate; HF, heart failure; JVP, jugular venous pressure; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; PVD, 
peripheral vascular disease; WBC, white blood cells. 
[1] Results shown are mean (standard deviation), median (25th - 75th percentile) for continuous variables, or prevalence (%) for categorical variables, unless 
otherwise noted. Numbers may vary due to missing values. 
[2] P-values from ANOVA (F-test) for continuous variables, or from Chi-squared test for categorical variables, unless otherwise noted. 
 
  
Supplemental table 3: Baseline characteristics by death up to 90 days after discharge 
 
-------------------------------- Death up to 90 days after discharge [1] ------------------------
--------  
Parameter 
n (% 
missing) Category No (N = 1749) Yes (N = 153) P-value [2] 
Age, y 1902 (0.0%)  69.8 (11.67), 72.0 (62.0 - 78.0) 71.8 (11.24), 73.0 (64.0 - 80.0) 0.0380 
Male sex 1902 (0.0%)  1169 (66.8%) 106 (69.3%) 0.5376 
White race 1889 (0.7%)  1653 (95.2%) 145 (95.4%) 0.8987 
Time from presentation to rand., 
h 
1885 (0.9%)  14.9 (13.24), 17.2 (5.6 - 21.7) 14.0 (8.22), 16.4 (5.2 - 21.6) 0.4084 
Ischemic heart disease 1900 (0.1%)  1196 (68.5%) 115 (75.2%) 0.0856 
History of angina 1898 (0.2%)  378 (21.6%) 35 (23.0%) 0.6932 
Previous stroke or PVD 1902 (0.0%)  310 (17.7%) 39 (25.5%) 0.0173 
Diabetes mellitus 1901 (0.1%)  797 (45.6%) 75 (49.0%) 0.4150 
Respiratory disease 1898 (0.2%)  334 (19.1%) 43 (28.3%) 0.0066 
Mitral regurgitation 1899 (0.2%)  583 (33.4%) 61 (39.9%) 0.1046 
History of atrial 
fibrillation/flutter 
1888 (0.7%)  933 (53.7%) 80 (53.0%) 0.8624 
History of CHF 1902 (0.0%)  1661 (95.0%) 145 (94.8%) 0.9149 
History of hypertension 1902 (0.0%)  1398 (79.9%) 116 (75.8%) 0.2259 
History of hyperlipidemia 1901 (0.1%)  915 (52.3%) 87 (56.9%) 0.2832 
History of smoking 1898 (0.2%)  362 (20.7%) 34 (22.4%) 0.6341 
History of CABG or PCI 1892 (0.5%)  656 (37.7%) 72 (47.1%) 0.0229 
 
-------------------------------- Death up to 90 days after discharge [1] ------------------------
--------  
Parameter 
n (% 
missing) Category No (N = 1749) Yes (N = 153) P-value [2] 
HF hospitalization in previous 
year 
1902 (0.0%)  836 (47.8%) 91 (59.5%) 0.0056 
NYHA class in previous month 1900 (0.1%) None/I/II 396 (22.6%) 24 (15.9%) 0.1497 
  III 841 (48.1%) 77 (51.0%)  
  IV 512 (29.3%) 50 (33.1%)  
BMI, kg/m**2 1880 (1.2%)  28.87 (6.132), 27.77 (24.53 - 31.91) 28.30 (6.314), 27.18 (23.89 - 30.95) 0.2716 
Heart rate, bpm 1900 (0.1%)  80.1 (15.43), 78.0 (70.0 - 90.0) 80.2 (15.47), 79.0 (69.0 - 90.0) 0.9615 
Systolic blood pressure, mmHg 1902 (0.0%)  125.4 (17.41), 125.0 (110.0 - 140.0) 117.5 (16.60), 115.0 (103.0 - 130.0) <.0001 
Diastolic blood pressure, mmHg 1902 (0.0%)  74.2 (11.83), 74.0 (67.0 - 80.0) 70.3 (11.45), 70.0 (60.0 - 80.0) <.0001 
Pulse pressure, mmHg 1902 (0.0%)  51.2 (15.03), 50.0 (40.0 - 60.0) 47.2 (14.70), 46.0 (38.0 - 55.0) 0.0019 
Mean arterial pressure, mmHg 1902 (0.0%)  91.26 (12.007), 91.00 (83.33 - 100.00) 86.06 (11.454), 86.00 (77.67 - 93.33) <.0001 
Respiratory rate, breaths per 
min 
1813 (4.7%)  21.3 (4.24), 21.0 (18.0 - 24.0) 20.6 (3.76), 20.0 (18.0 - 23.0) 0.0616 
Edema 1902 (0.0%) 0 249 (14.2%) 26 (17.0%) 0.1192 
  >1 326 (18.6%) 24 (15.7%)  
  >2 717 (41.0%) 52 (34.0%)  
  >3 457 (26.1%) 51 (33.3%)  
JVP 1717 (9.7%) <6 cm 188 (11.9%) 16 (11.3%) 0.9793 
  6-10 cm 755 (47.9%) 68 (48.2%)  
 
-------------------------------- Death up to 90 days after discharge [1] ------------------------
--------  
Parameter 
n (% 
missing) Category No (N = 1749) Yes (N = 153) P-value [2] 
  >10 cm 633 (40.2%) 57 (40.4%)  
Orthopnea 1877 (1.3%) None 67 (3.9%) 9 (6.0%) 0.4445 
  1 pillow 210 (12.2%) 17 (11.3%)  
  2 pillows 708 (41.0%) 55 (36.4%)  
  >30° 741 (42.9%) 70 (46.4%)  
Rales 1899 (0.2%) 0 167 (9.6%) 15 (9.8%) 0.0081 
  <1/3 509 (29.2%) 55 (35.9%)  
  1/3 to 2/3 910 (52.1%) 60 (39.2%)  
  >2/3 160 (9.2%) 23 (15.0%)  
Hemoglobin, g/dL 1662 
(12.6%) 
 12.72 (1.977), 12.60 (11.30 - 14.10) 12.41 (1.954), 12.30 (11.10 - 13.70) 0.0863 
WBC count, x10**9/L 1662 
(12.6%) 
 7.87 (2.937), 7.42 (6.04 - 9.15) 8.55 (4.826), 7.50 (6.25 - 9.89) 0.0154 
Sodium, mEq/L 1846 (2.9%)  139.6 (3.96), 140.0 (137.0 - 142.0) 137.7 (4.62), 138.0 (135.0 - 141.0) <.0001 
Potassium, mEq/L 1750 (8.0%)  4.27 (0.569), 4.20 (3.90 - 4.60) 4.33 (0.626), 4.40 (3.90 - 4.70) 0.1736 
Bicarbonate, mEq/L 1771 (6.9%)  24.1 (3.69), 24.0 (22.0 - 26.0) 23.2 (4.55), 23.0 (20.0 - 26.0) 0.0109 
Creatinine, mg/dL 1843 (3.1%)  1.49 (0.566), 1.40 (1.10 - 1.70) 1.72 (0.638), 1.50 (1.20 - 2.20) <.0001 
eGFR, mL/min 1840 (3.3%)  49.27 (18.463), 47.32 (35.82 - 60.40) 42.81 (19.247), 39.31 (28.24 - 51.83) <.0001 
BUN, mg/dL 1848 (2.8%)  32.6 (16.41), 28.0 (21.0 - 39.0) 43.6 (20.61), 39.0 (28.0 - 54.0) <.0001 
 
-------------------------------- Death up to 90 days after discharge [1] ------------------------
--------  
Parameter 
n (% 
missing) Category No (N = 1749) Yes (N = 153) P-value [2] 
BUN/creatinine ratio 1843 (3.1%)  21.96 (6.864), 20.77 (17.22 - 25.45) 25.60 (8.274), 24.35 (18.89 - 31.52) <.0001 
Uric acid, mg/dL 1771 (6.9%)  527.89 (149.557), 517.48 (422.31 - 
624.54) 
590.95 (156.937), 582.90 (484.76 - 
704.84) 
<.0001 
Albumin, g/dL 1842 (3.2%)  3.86 (0.434), 3.90 (3.60 - 4.20) 3.81 (0.384), 3.80 (3.60 - 4.00) 0.1873 
ALT, U/L 1721 (9.5%)  29.2 (29.23), 21.0 (15.0 - 32.0) 32.9 (42.59), 20.0 (14.0 - 32.0) 0.1732 
Glucose, mg/dL 1787 (6.0%)  7.85 (3.268), 6.99 (5.72 - 9.10) 7.65 (2.810), 6.94 (5.77 - 9.38) 0.4790 
Cholesterol, mg/dL 1841 (3.2%)  3.86 (1.135), 3.72 (3.06 - 4.51) 3.49 (1.081), 3.37 (2.80 - 4.20) 0.0001 
Triglycerides, mg/dL 1829 (3.8%)  102.3 (52.51), 90.0 (65.0 - 126.0) 92.3 (44.31), 82.0 (59.0 - 115.0) 0.0273 
  
Notes: 
ALT, alanine transferase; BMI, body mass index; BUN, blood urea nitrogen; CABG, coronary artery bypass graft; CHF, chronic heart failure; eGFR, estimated 
glomerular filtration rate; HF, heart failure; JVP, jugular venous pressure; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; PVD, 
peripheral vascular disease; WBC, white blood cells. 
[1] Results shown are mean (standard deviation), median (25th - 75th percentile) for continuous variables, or prevalence (%) for categorical variables, unless 
otherwise noted. Numbers may vary due to missing values. 
[2] P-values from ANOVA (F-test) for continuous variables, or from Chi-squared test for categorical variables, unless otherwise noted. 
 
